Pupalan Iyngkaran*, Fahad Hanna, Maximilian De Courten, Sharmalar Rajendran
Iyngkaran et al. J Clin Transl Res 2023; 9(5):23-00010
Published online: September 30, 2023
Background & aim: Congestive heart failure (CHF) imposes a relevant burden on healthcare systems, as it is associated with high morbidity and mortality rates and considerable costs. Within the last three to four decades, there have been revolutionary advancements, particularly in the pharmaceutical industry. In addition, health services research at the population level has also delivered. A third avenue for advancing the clinical management of CHF is to explore established therapies with a new approach. In this perspective, we explore these established concepts and provide impetus for using bedside observations to find improvements in CHF outcomes.
Conclusion: There are potentially new concepts that can be brought to established solutions for CHF. Encouraging observations when delivering established guideline-directed medical therapies are issues that the evidence-based medicine community should factor alongside novel discoveries to improve CHF prognosis. An emphasis on innovating on the known can be considered as an important paradigm for discovery.
Relevance for patients: Patients with CHF receiving current available treatments have improved outcomes; however those not improving could be considered under evolving research paradigms.
1. Melbourne Clinical School The University of Notre Dame, Melbourne, Victoria, Australia
2. Program of Public Health, Torrens University, Melbourne, Victoria, Australia
3. Mitchell Institute, Victoria University, Melbourne, Victoria, Australia
4. Northern Adelaide Local Health Network, South Australia, Australia
Melbourne Clinical School, The University of Notre Dame, Melbourne, Victoria, Australia.
Program of Public Health, Torrens University, Melbourne, Victoria Australia.
Department of Pharmaceutics, Utrecht University, the Netherlands
Department of Chemistry, Utrecht University, Utrecht, the Netherlands
Department of Pathology, Erasmus Medical Center, the Netherlands
Department of Pharmaceutics, Jiaxing University Medical College, Zhejiang, China
Full text PDF